Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of Chronocort versus immediate-release hydrocortisone in congenital adrenal hyperplasia
2021-003668-29Phase 3Completed
- Sponsor
- Diurnal Group plc
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in 21-hydroxylase deficiency (21-OHD) comparing Chronocort with Immediate-release hydrocortisone (2 arms). Primary endpoint: Biochemical responder rate at 52 weeks. Started Dec 2021; status: completed.
02
Drugs
hydrocortisone modified-releasehydrocortisone
03
Conditions
21-hydroxylase deficiency (21-OHD)
Beyond the preview
Go deeper on 2021-003668-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003668-29.